Neural Correlates In Mild Alzheimer's Disease
| Status: | Completed |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 10/14/2017 |
| Start Date: | July 2007 |
| End Date: | August 2008 |
A Single Center Study To Examine Neural Correlates Of Cognition In Subjects With Mild Alzheimer's Disease After Three Months Of Open Label Donepezil HCl (Aricept® ) Treatment
The objective of this study is to identify neural correlates of cognitive improvement after
three months of donepezil HCl in subjects with mild Alzheimer's Disease (AD), measuring the
Functional Hippocampus Connectivity Index (HCI) and Cerebral Blood Flow (CBF) Perfusion in
the Medial Temporal Lobe network. The hypothesis is that donepezil HCl will improve MTL
connectivity and CBF Perfusion in the MTL-projected target regions, which will significantly
correlate with cognitive improvement in mild AD subjects.
three months of donepezil HCl in subjects with mild Alzheimer's Disease (AD), measuring the
Functional Hippocampus Connectivity Index (HCI) and Cerebral Blood Flow (CBF) Perfusion in
the Medial Temporal Lobe network. The hypothesis is that donepezil HCl will improve MTL
connectivity and CBF Perfusion in the MTL-projected target regions, which will significantly
correlate with cognitive improvement in mild AD subjects.
Inclusion Criteria:
- Men and women, aged 50 and older with mild Alzheimer's disease (MMSE scores of 20 to
30 are allowed).
- Diagnostic evidence of Alzheimer's disease.
- Previous use of cholinesterase inhibitors (other than Aricept) and memantine allowed.
Exclusion Criteria:
- Prior use of Aricept, pacemakers and insulin dependent diabetes are not allowed.
We found this trial at
1
site
Click here to add this to my saved trials
